Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vaxxinity, Inc. (VAXX)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
1717 Main Street 75201
Dallas, TX, US
Dallas, TX, US
CEO
Mei Mei Hu
Website
vaxxinity.com
IPO
2021-11-11
CIK 1851657 ISIN US92244V1044
Description
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
12.6K
Beta
3.78
Float Shares
60.28M
Free Float %
47.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -66.67% | -50.00% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-15.19
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+99.9% ★ Q4'23: +43.8% (vs Q4'22)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'23: +2,466.4% (vs Q4'22)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q4'23: +0.9% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.28× Q4'23: -0.35× (vs Q4'22)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
66.0K
est: 50.0K (+32.0%)
|
—
|
13.40M
est.
|
30.80M
est.
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-135.23M
est: 10.0K (-1,352,565.2%)
|
-54.00M
|
2.68M
est.
|
6.16M
est.
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBIT |
-136.34M
est: 10.0K (-1,363,586.3%)
|
-56.24M
|
2.68M
est.
|
6.16M
est.
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Net Income |
-137.18M
est: -198.62M (+30.9%)
|
-56.9K
est: -58.19M (+99.9%)
|
-48.07M
est.
|
-49.34M
est.
|
-51.87M
-51.87M – -51.87M
-5.1% YoY
|
-51.87M
-51.87M – -51.87M
+0.0% YoY
|
| SGA |
51.83M
est: 8.10M (+539.7%)
|
22.39M
|
2.17B
est.
|
4.99B
est.
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EPS |
-1.09
est: -1.57 (+30.6%)
|
0.00
est: -0.46 (+99.9%)
|
-0.38
est.
|
-0.39
est.
|
-0.41
-0.41 – -0.41
-5.1% YoY
|
-0.41
-0.41 – -0.41
+0.0% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-57.24M
OE per share TTM
-0.45
Owner's Yield
-449,918.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
7,750.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
43.00
Insider transactions (90d)
0
Beneficial owners (>5%)
12
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mei Mei Hu | 77.80M | 69.50% | 73.58M | 4.21M | 10.48M | 271.7K | IN | United States | 2022-04-27 | ↗ |
| 2 | United Biomedical, Inc. | 57.73M | 51.60% | — | — | 53.52M | 4.21M | CO | Delaware | 2022-04-27 | ↗ |
| 3 | Dakin Sloss | 18.03M | 16.20% | — | 18.03M | — | 18.03M | IN | — | 2022-02-09 | ↗ |
| 4 | Prime Movers Lab GP I LLC | 12.03M | 10.80% | — | 12.03M | — | 12.03M | PN | — | 2022-02-09 | ↗ |
| 5 | Prime Movers Lab Fund I LP | 9.74M | 8.70% | — | 9.74M | — | 9.74M | PN | — | 2022-02-09 | ↗ |
| 6 | Lou Reese | 9.58M | 8.60% | — | — | 9.31M | 271.7K | IN | United States | 2022-04-27 | ↗ |
| 7 | Prime Movers Growth Fund 1 LP | 3.62M | 3.20% | — | 3.62M | — | 3.62M | PN | — | 2022-02-09 | ↗ |
| 8 | Prime Movers Growth GP I LLC | 3.62M | 3.20% | — | 3.62M | — | 3.62M | PN | — | 2022-02-09 | ↗ |
| 9 | Prime Movers Lab GP II LLC | 2.38M | 2.10% | — | 2.38M | — | 2.38M | PN | — | 2022-02-09 | ↗ |
| 10 | COVAXX PML SPV 1 LP | 2.29M | 2.10% | — | 2.29M | — | 2.29M | PN | — | 2022-02-09 | ↗ |
| 11 | COVAXX PML SPV 3 LP | 1.52M | 1.40% | — | 1.52M | — | 1.52M | PN | — | 2022-02-09 | ↗ |
| 12 | COVAXX PML SPV 2 LP | 861.9K | 0.80% | — | 861.9K | — | 861.9K | PN | — | 2022-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NBC SECURITIES, INC. | 1.6K +1.6K (+100.0%) | 43.00 +43.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD0.03 +0.0% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
159.7K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+159,744
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-03 | Paula Molina Rene | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-01 | Ray Sumita | Officer | A-Award | A | Employee Stock option (right to buy) | 425,000 | 1.17 | 497.3K | 425,000 | — | ↗ |
| 2023-10-02 | Powchik Peter | Director | A-Award | A | Stock option (right to buy) | 159,744 | 1.27 | 202.9K | 159,744 | — | ↗ |
| 2023-10-01 | Ray Sumita | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-08 | Prime Movers Lab Fund I LP | 10% Owner | S-Sale | D | Class A Common Stock | 2,395 | 1.67 | 4.0K | 831,658 | — | ↗ |
| 2023-09-07 | Prime Movers Lab Fund I LP | 10% Owner | S-Sale | D | Class A common stock | 3,413 | 1.79 | 6.1K | 1,468,795 | — | ↗ |
| 2023-09-06 | Prime Movers Lab Fund I LP | 10% Owner | S-Sale | D | Class A Common Stock | 507 | 1.88 | 954.33 | 835,992 | — | ↗ |
| 2023-06-20 | TOLEDANO GABRIELLE B | Director | A-Award | A | Stock option (right to buy) | 132,352 | 2.21 | 292.5K | 132,352 | — | ↗ |
| 2023-06-20 | Smith James Alan | Director | A-Award | A | Stock option (right to buy) | 132,352 | 2.21 | 292.5K | 132,352 | — | ↗ |
| 2023-06-20 | Powchik Peter | Director | A-Award | A | Stock option (right to buy) | 132,352 | 2.21 | 292.5K | 132,352 | — | ↗ |
| 2023-06-20 | Ogilvie Landon E | Director | A-Award | A | Stock option (right to buy) | 132,352 | 2.21 | 292.5K | 132,352 | — | ↗ |
| 2023-06-20 | HORNIG GEORGE R | Director | A-Award | A | Stock option (right to buy) | 132,352 | 2.21 | 292.5K | 132,352 | — | ↗ |
| 2023-06-20 | Eade Katherine A. | Director | A-Award | A | Stock option (right to buy) | 132,352 | 2.21 | 292.5K | 132,352 | — | ↗ |
| 2023-06-20 | Diamandis Peter | Director | A-Award | A | Stock option (right to buy) | 132,352 | 2.21 | 292.5K | 132,352 | — | ↗ |
| 2023-04-26 | Diamandis Peter | Director | M-Exempt | A | Class A common stock | 46,500 | 1.21 | 56.3K | 906,141 | — | ↗ |
| 2023-03-07 | Reese Lou | Director / Officer | A-Award | A | Stock Option (right to buy) | 301,188 | 2.29 | 689.7K | 301,188 | — | ↗ |
| 2023-03-07 | Pesile Jason | Officer | A-Award | A | Stock Option (right to buy) | 32,700 | 2.29 | 74.9K | 32,700 | — | ↗ |
| 2023-03-07 | Paula Molina Rene | Officer | A-Award | A | Stock Option (right to buy) | 116,612 | 2.29 | 267.0K | 116,612 | — | ↗ |
| 2023-03-07 | Palm Ulo | Officer | A-Award | A | Stock Option (right to buy) | 123,418 | 2.29 | 282.6K | 123,418 | — | ↗ |
| 2023-03-07 | Hu Mei Mei | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 620,000 | 2.29 | 1.42M | 620,000 | — | ↗ |
| 2023-02-01 | TOLEDANO GABRIELLE B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-01 | Smith James Alan | Director | — | — | Class A common stock | 0 | 0.00 | — | 8,058 | D | ↗ |
| 2023-02-01 | Ogilvie Landon E | Director | — | I | Class A common stock | 0 | 0.00 | — | 32,850 | — | ↗ |
| 2023-02-01 | Eade Katherine A. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-01-23 | Prime Movers Lab Fund I LP | Director | S-Sale | D | Class A common stock | 405,217 | 3.35 | 1.36M | 8,764,372 | — | ↗ |
| 2022-12-02 | Prime Movers Lab Fund I LP | Director | S-Sale | D | Class A Common Stock | 11,121 | 2.57 | 28.6K | 9,169,589 | — | ↗ |
| 2022-12-01 | Prime Movers Lab Fund I LP | Director | S-Sale | D | Class A Common Stock | 270,964 | 2.97 | 805.2K | 9,180,710 | — | ↗ |
| 2022-09-06 | Sloss Dakin | Director | S-Sale | D | Class A Common Stock | 25,243 | 2.40 | 60.7K | 9,451,674 | — | ↗ |
| 2022-08-23 | Sloss Dakin | Director | S-Sale | D | Class A Common Stock | 83,786 | 2.39 | 199.9K | 9,499,674 | — | ↗ |
| 2022-08-22 | Guirakhoo Farshad | Officer | M-Exempt | A | Class A common stock | 2,640 | 0.57 | 1.5K | 68,645 | — | ↗ |
| 2022-08-15 | Guirakhoo Farshad | Officer | M-Exempt | A | Class A common stock | 26,005 | 0.57 | 14.8K | 66,005 | — | ↗ |
| 2022-07-29 | Guirakhoo Farshad | Officer | M-Exempt | A | Class A common stock | 20,000 | 0.57 | 11.4K | 40,000 | — | ↗ |
| 2022-06-21 | Powchik Peter | Director | A-Award | A | Stock option (right to buy) | 129,187 | 0.00 | — | 129,187 | — | ↗ |
| 2022-06-21 | HORNIG GEORGE R | Director | A-Award | A | Stock option (right to buy) | 129,187 | 0.00 | — | 129,187 | — | ↗ |
| 2022-06-21 | Diamandis Peter | Director | A-Award | A | Stock option (right to buy) | 129,187 | 0.00 | — | 129,187 | — | ↗ |
| 2022-06-21 | Chui James | Director | A-Award | A | Stock option (right to buy) | 129,187 | 0.00 | — | 129,187 | — | ↗ |
| 2022-06-21 | BLATT GREGORY R | Director | A-Award | A | Stock option (right to buy) | 129,187 | 0.00 | — | 129,187 | — | ↗ |
| 2022-06-16 | UNITED BIOMEDICAL INC | Director | P-Purchase | A | Class A common stock | 100,000 | 1.99 | 199.3K | 51,737,344 | — | ↗ |
| 2022-06-16 | Reese Lou | Officer | P-Purchase | A | Class A common stock | 100,000 | 1.99 | 199.3K | 51,737,344 | — | ↗ |
| 2022-06-16 | Hu Mei Mei | Officer | P-Purchase | A | Class A common stock | 100,000 | 1.99 | 199.3K | 51,737,344 | — | ↗ |
| 2022-06-10 | Sloss Dakin | Director | S-Sale | D | Class A Common Stock | 8,193 | 2.43 | 19.9K | 851,152 | — | ↗ |
| 2022-06-08 | UNITED BIOMEDICAL INC | Director | P-Purchase | A | Class A common stock | 10,978 | 2.72 | 29.9K | 51,637,344 | — | ↗ |
| 2022-06-08 | Reese Lou | Officer | P-Purchase | A | Class A common stock | 10,000 | 2.95 | 29.5K | 51,626,366 | — | ↗ |
| 2022-06-08 | Hu Mei Mei | Officer | P-Purchase | A | Class A common stock | 10,978 | 2.72 | 29.9K | 51,637,344 | — | ↗ |
| 2022-05-03 | Guirakhoo Farshad | Officer | M-Exempt | D | Stock Option (right to buy) | 10,000 | 0.57 | 5.7K | 116,730 | — | ↗ |
| 2022-04-26 | UNITED BIOMEDICAL INC | Director | P-Purchase | A | Class A common stock | 4,807 | 3.58 | 17.2K | 51,616,366 | — | ↗ |
| 2022-04-26 | Reese Lou | Officer | P-Purchase | A | Class A common stock | 4,807 | 3.58 | 17.2K | 51,616,366 | — | ↗ |
| 2022-04-26 | Hu Mei Mei | Officer | P-Purchase | A | Class A common stock | 4,807 | 3.58 | 17.2K | 51,616,366 | — | ↗ |
| 2022-04-25 | UNITED BIOMEDICAL INC | Director | P-Purchase | A | Class A common stock | 8,038 | 3.37 | 27.1K | 5,193,454 | — | ↗ |
| 2022-04-25 | Reese Lou | Officer | P-Purchase | A | Class A common stock | 8,038 | 3.37 | 27.1K | 51,593,454 | — | ↗ |
| 2022-04-25 | Hu Mei Mei | Officer | P-Purchase | A | Class A common stock | 8,038 | 3.37 | 27.1K | 51,593,454 | — | ↗ |
| 2022-03-31 | Powchik Peter | Director | — | D | Class A common stock | 0 | 0.00 | — | 225,858 | — | ↗ |
| 2022-03-15 | Palm Ulo | Officer | A-Award | A | Restricted Stock Units | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-01-24 | Diamandis Peter | Director | M-Exempt | A | Class A common stock | 652,764 | 4.12 | 2.69M | 729,687 | — | ↗ |
| 2022-01-13 | Guirakhoo Farshad | Officer | M-Exempt | A | Class A common stock | 10,000 | 0.57 | 5.7K | 10,000 | — | ↗ |
| 2022-01-03 | Pesile Jason | Officer | A-Award | A | Stock Option (right to buy) | 51,225 | 5.96 | 305.3K | 51,225 | — | ↗ |
| 2022-01-03 | HORNIG GEORGE R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | Chui James | Director | P-Purchase | A | Class A common stock | 6,000 | 5.48 | 32.9K | 14,000 | — | ↗ |
| 2021-12-10 | Chui James | Director | P-Purchase | A | Class A common stock | 8,000 | 7.89 | 63.1K | 8,000 | — | ↗ |
| 2021-11-18 | Diamandis Peter | Director | S-Sale | D | Class A common stock | 248 | 13.00 | 3.2K | 90,499 | — | ↗ |
| 2021-11-16 | BLATT GREGORY R | Director | J-Other | A | Class A common stock | 76,923 | 0.00 | — | 76,923 | — | ↗ |
| 2021-11-15 | UNITED BIOMEDICAL INC | 10% Owner | C-Conversion | D | Series A preferred stock | 6,554,643 | 0.00 | — | 0 | — | ↗ |
| 2021-11-15 | Reese Lou | Director / Officer | C-Conversion | A | Class A common stock | 247,050 | 0.00 | — | 51,585,416 | — | ↗ |
| 2021-11-15 | Prime Movers Lab Fund I LP | 10% Owner | C-Conversion | D | Series A preferred stock | 15,152,627 | 0.00 | — | 0 | — | ↗ |
| 2021-11-15 | Palm Ulo | Officer | P-Purchase | A | Class A common stock | 450 | 13.00 | 5.9K | 450 | — | ↗ |
| 2021-11-15 | Hu Mei Mei | Director / Officer / 10% Owner | C-Conversion | A | Class A common stock | 247,050 | 0.00 | — | 51,585,416 | — | ↗ |
| 2021-11-15 | Diamandis Peter | Director | P-Purchase | A | Class A common stock | 76,923 | 0.00 | — | 76,923 | — | ↗ |
| 2021-11-15 | BLATT GREGORY R | Director | C-Conversion | D | Series A preferred stock | 83,329 | 0.00 | — | 0 | — | ↗ |
| 2021-11-12 | Reese Lou | Director / Officer | P-Purchase | A | Class A common stock | 17,500 | 13.82 | 241.9K | 17,500 | — | ↗ |
| 2021-11-12 | Hu Mei Mei | Director / Officer / 10% Owner | P-Purchase | A | Class A common stock | 17,500 | 13.82 | 241.9K | 17,500 | — | ↗ |
| 2021-11-11 | Paula Molina Rene | Officer | A-Award | A | Stock option (right to buy) | 96,153 | 13.00 | 1.25M | 96,153 | — | ↗ |
| 2021-11-11 | Palm Ulo | Officer | A-Award | A | Stock option (right to buy) | 233,100 | 13.00 | 3.03M | 233,100 | — | ↗ |
| 2021-11-11 | Guirakhoo Farshad | Officer | A-Award | A | Stock option (right to buy) | 41,958 | 13.00 | 545.5K | 41,958 | — | ↗ |
| 2021-11-10 | UNITED BIOMEDICAL INC | 10% Owner | — | D | Class A common stock | 0 | 0.00 | — | 51,338,366 | — | ↗ |
| 2021-11-10 | Reese Lou | Director / Officer | — | D | Stock option (right to buy) | 2,346,709 | 0.28 | 666.5K | 0 | — | ↗ |
| 2021-11-10 | Prime Movers Lab Fund I LP | 10% Owner | — | I | Series B preferred stock | 5,625,000 | 0.00 | — | 0 | — | ↗ |
| 2021-11-10 | Paula Molina Rene | Officer | — | D | Stock option (right to buy) | 223,311 | 4.01 | 895.3K | 0 | — | ↗ |
| 2021-11-10 | Palm Ulo | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-10 | Hu Mei Mei | Director / Officer / 10% Owner | — | D | Stock option (right to buy) | 378,785 | 10.07 | 3.81M | 0 | — | ↗ |
| 2021-11-10 | Guirakhoo Farshad | Officer | — | D | Stock option (right to buy) | 126,730 | 0.57 | 72.0K | 0 | — | ↗ |
| 2021-11-10 | Doran Martin | Officer | — | D | Class A common stock | 0 | 0.00 | — | 22,688 | — | ↗ |
| 2021-11-10 | Diamandis Peter | Director | — | I | Series A preferred stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-10 | Chui James | Director | — | D | Stock option (right to buy) | 464,680 | 4.12 | 1.91M | 0 | — | ↗ |
| 2021-11-10 | BLATT GREGORY R | Director | — | I | Series B preferred stock | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
126.78M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sumita Ray | Chief Legal, Compliance & Administrative Officer and Corporate Secretary | 465.6K | female |
| Mei Mei Hu | Co-Founder, President, Chief Executive Officer & Director | 345.1K | female |
| Louis Garfield Reese | Co-Founder & Executive Chairman of the Board | 275.6K | male |
| Mark Joinnides | Chief of Staff | — | male |
| Manal Morsy | Chief Regulatory Officer | — | — |
| Jean-Cosme Dodart | Chief Scientific Officer | — | — |
| Jason Pesile | Chief Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-12-20 | 2024-01-19 | Rick Scott | FL | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VAXX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
